X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Appili to present update on topical formulation of paromomycin, ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
The net proceeds of the Offering will be used primarily for working capital purposes and to fund the development of certain product candidates including ATI-1801 (paromomycin) of the Company.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2022
Details:
The net proceeds of the Offering will be used primarily for working capital purposes and to fund the development of certain product candidates of the Company. Details as to the specific allocation of the proceeds will be disclosed in the Prospectus Supplement.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 17, 2022
Details:
The study met its primary endpoint, with ATI-1801 administered topically once daily for 20 days demonstrating a significant improvement in the rate of clinical cure of the index lesion compared to vehicle (82% vs 58%; p-value < 0.001).
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
